Fenspiride

Summary

Fenspiride (CHEMBL576127) is an approved small molecule (ATC R03DX03); indicated across 1 condition including obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03DX03 (+1 more)
• Indications: 1 condition
• Chemistry: 260.33 Da · C15H20N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL576127
Name	Fenspiride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3344
ATC	R03DX03, R03BX01
Molecular formula	C15H20N2O2
Molecular weight	260.33
InChIKey	FVNFBBAOMBJTST-UHFFFAOYSA-N

SMILES: C1CN(CCC12CNC(=O)O2)CCC3=CC=CC=C3

IUPAC name: 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one

Also known as: Eurespal, Fenspirida, Fenspiride, SID11111183, SID11112904, SID90341038, FENSPIRIDE, FENSPIRIDE HYDROCHLORIDE, fenspiride

Parent form; salt/anhydrous children: CHEMBL1256849

Patent coverage: 14,903 distinct patent families (26,246 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26,235 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Prelamin-A/C, Alpha-2A adrenergic receptor, Thyrotropin receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.46	Potency	3.5	nM	CHEMBL_ACT_3649364
P08482	5.25	Potency	5623	nM	CHEMBL_ACT_4811359
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3922175
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_4619280
ADRA2A	5.09	AC50	8198	nM	CHEMBL_ACT_25156674

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).